Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Expanding horizons in metastatic prostate cancer treatment

Nature Reviews Clinical Oncology volume 8, page 625 (2011)Cite this article

Subjects

We read with interest the recent, comprehensive review by Sturge et al. (Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat. Rev. Clin. Oncol. 8, 357–368)1 that describes current and emerging therapies for bone metastases in patients with castration-resistant prostate cancer (CRPC). However, we noted several factual errors and additional points that we consider should be further clarified.

The authors claim an overall survival benefit for clodronate treatment in men with bone metastases from CRPC on the basis of the data from the Medical Research Council (MRC) PR05 trial.2 However, patients with bone metastases enrolled in this trial did not have castration-resistant disease. Furthermore, as overall survival was not reported in the entire cohort in the MRC PR05 trial, it is difficult to draw definitive conclusions on the impact of clodronate on survival in men with metastatic prostate cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sturge, J., Caley, M. P. & Waxman, J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat. Rev. Clin. Oncol. 8, 357–368 (2011).

    Article  CAS  Google Scholar 

  2. Dearnaley, D. P., Mason, M. D., Parmar, M. K., Sanders, K. & Sydes, M. R. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 10, 872–876 (2009).

    Article  CAS  Google Scholar 

  3. Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 377, 813–822 (2011).

    Article  CAS  Google Scholar 

  4. Fizazi, K. et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer [abstract]. J. Clin. Oncol. 28 (Suppl. 18), LBA4507 (2010).

    Article  Google Scholar 

  5. Weiner, L. M. Fully human therapeutic monoclonal antibodies. J. Immunother. 29, 1–9 (2006).

    Article  CAS  Google Scholar 

  6. US National Library of Medicine. ClinicalTrials.gov[online], (2011).

  7. US National Library of Medicine. ClinicalTrials.gov[online], (2010).

  8. US National Library of Medicine. ClinicalTrials.gov[online], (2009).

  9. Smith, M. R. et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745–755 (2009).

    Article  CAS  Google Scholar 

  10. US National Library of Medicine. ClinicalTrials.gov[online], (2010).

Download references

Acknowledgements

Amy Foreman-Wykert (Amgen Inc.) assisted in draft preparation and formatting of the correspondence.

Author information

Authors and Affiliations

  1. Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, 39 rue Camille Desmoulins, Villejuif, 94805, France

    Karim Fizazi

  2. Clinical Development, Amgen Inc., One Amgen Center Drive, MS 38-2-A, Thousand Oaks, 91320, CA, USA

    Carsten Goessl

Authors
  1. Karim Fizazi
    View author publications

    Search author on:PubMed Google Scholar

  2. Carsten Goessl
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Karim Fizazi.

Ethics declarations

Competing interests

K. Fizazi is a consultant for Amgen and Novartis, and has participated in speakers' bureaus for Amgen and Novartis. C. Goessl is an employee and shareholder of Amgen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fizazi, K., Goessl, C. Expanding horizons in metastatic prostate cancer treatment. Nat Rev Clin Oncol 8, 625 (2011). https://doi.org/10.1038/nrclinonc.2011.67-c1

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrclinonc.2011.67-c1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer